Entrada Therapeutics Inc(TRDA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.97 | Insider Own | 38.6% | Shs Outstand | 38.9M | Perf Week | 7.58% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | 10.58% | Insider Trans | -8.96% | Shs Float | 23.9M | Perf Month | -5.02% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -1.01 | Inst Own | 53.48% | Short Float | 13.68% | Perf Quarter | -29.42% |
| Income | -0.17B | P/S | 42.42 | EPS this Y | -15.52% | Inst Trans | 1.48% | Short Ratio | 9.5 | Perf Half Y | -67.64% |
| Sales | 0.00B | P/B | 0.85 | EPS next 5Y | 2.76% | ROA | -44.35% | Short Interest | 3.27M | Perf YTD | -50.29% |
| Book/sh | 5.99 | P/C | 0.89 | EPS past 3/5Y | -4.74% -32.56% | ROE | -54.09% | 52W High | -68.94% ($16.45) | Perf Year | -26.47% |
| Cash/sh | 5.73 | P/FCF | - | Sales past 3/5Y | - | ROIC | -59.74% | 52W Low | 24.36% ($4.11) | Perf 3Y | -67.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -122.58% | Gross Margin | 21.23% | Volatility(W/M) | 12.7% 9.93% | Perf 5Y | -79.95% |
| Dividend TTM | - | EV/Sales | 5.23 | Sales Y/Y TTM | -94.1% | Oper. Margin | -3767.07% | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.89 | EPS Q/Q | 2.87% | Profit Margin | -3537.73% | RSI (14) | 49.07 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.89 | Sales Q/Q | -53.95% | SMA20 | 4.35% ($4.9) | Beta | -0.19 | Target Price | $17 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 2026/8/5 | SMA50 | -14.78% ($6) | Rel Volume | 1.89 | Prev Close | $4.53 |
| Employees | 152 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | 3.75% -59.81% | SMA200 | -41.54% ($8.74) | Avg Volume(3M) | 0.34M | Price | $5.11 |
| IPO | 2021/10/29 | Option/Short | Yes/Yes | Trades | 4164 | Volume | 652,186 | Change | 12.68% |
A U.S. clinical-stage biotech company developing RNA therapeutics based on its proprietary endosomal escape delivery platform. It targets rare neuromuscular diseases, including Duchenne muscular dystrophy, as well as ophthalmologic conditions, with its intracellular drug delivery technology serving as its core competitive advantage.
Over the past 1 year, on the lower side
69% below its 1-year high.
Traded more than usual. That is 189% of its average volume.
TRDA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -15.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,242. Peers typically go for $946. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -80.0%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 53.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #299 of 597 in the industry
Based on market cap of $199M.
ARTV#297 Artiva Biotherapeutics Inc $205M PER - 
PYXS#298 Pyxis Oncology Inc $202M PER - TRDA#299 Entrada Therapeutics Inc $199M PER - 
INO#300 Inovio Pharmaceuticals Inc $195M PER - 
PALI#301 Palisade Bio Inc $195M PER - 
FAQ
What kind of company is TRDA?
TRDA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TRDA?
The market cap of TRDA is approximately $199M, ranking 4,007 within its sector.
What is the 52-week high and low for TRDA?
TRDA has recorded a 52-week high of $16.45 and a low of $4.11.
